Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.36 |
| ▸ | GSK3B | P49841 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.35 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.35 |
| ▸ | PTPRB | P23467 | 1/20 | 0.35 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.35 |
| ▸ | NPC1 | O15118 | 2/20 | 0.35 |
| ▸ | RAB9A | P51151 | 2/20 | 0.35 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | PPARG | P37231 | 1/20 | 0.34 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6775496 | 0.98 | ALDH1A1 (0.38) | ALDH1A1ALOX5PKMMAPK10GSK3B | |
| SCHEMBL31305794 | 0.81 | ALDH1A1 (0.37) | ALDH1A1MAPK10KDM4EPTPN2PTPRB | |
| SCHEMBL8823260 | 0.79 | ALDH1A1 (0.39) | ALDH1A1MAPK10KDM4EPTPN2PTPRB | |
| SCHEMBL28380222 | 0.77 | FABP4 (0.50) | ALDH1A1MAPK10KDM4EMEN1KMT2A | |
| SCHEMBL8823288 | 0.77 | ALDH1A1 (0.41) | ALDH1A1MAPK10KDM4EKMT2A | |
| SCHEMBL16585740 | 0.75 | ALDH1A1 (0.39) | ALDH1A1PKMKDM4EL3MBTL1 | |
| SCHEMBL28051084 | 0.75 | ALDH1A1 (0.39) | ALDH1A1PKMKDM4EL3MBTL1 | |
| SCHEMBL5049650 | 0.75 | PKM (0.45) | PKMMAPK10GSK3BKDM4EGAA | |
| SCHEMBL6857304 | 0.71 | PTPN2 (0.48) | PKMGSK3BKDM4EGAAPTPN2 | |
| SCHEMBL7748143 | 0.70 | MAPK10 (0.65) | ALDH1A1MAPK10KDM4EGAAL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105636975-A | Anti-inflammatory tripeptides | DR AUGUST WOLFF GMBH & CO KG ARZNEIMITTEL | 2016-06-01 | — | — | CN | claimed |
| US-6833382-B2 | By muta-synthesis using a mutated micro-organism to influence the biosynthesis of at least one of the precursors of group B streptogramines; mutant strain employed is preferably derived from the strain S. pristinaespiralis SP92 | AVENTIS PHARMA S.A. (FR) | 2004-12-21 | — | — | US | claimed |
| US-20020142947-A1 | STREPTOGRAMINS AND METHOD FOR PREPARING SAME BY MUTASYNTHESIS | AVENTIS PHARMA, S.A. | 2002-10-03 | — | — | US | claimed |
| CN-105636975-B | Anti-inflammatory tripeptides | 奥古斯特沃尔夫博士有限两合公司-医药 | 2019-06-25 | — | — | CN | disclosed |
| CN-105636975-A | Anti-inflammatory tripeptides | DR AUGUST WOLFF GMBH & CO KG ARZNEIMITTEL | 2016-06-01 | — | — | CN | disclosed |
| EP-2248901-A1 | Streptogramines and method for preparing same by mutasynthesis | Aventis Pharma S.A. (FR) | 2010-11-10 | — | — | EP | disclosed |
| EP-0770132-B1 | NEW STREPTOGRAMINES | AVENTIS PHARMA SA (FR) | 2010-09-08 | — | — | EP | disclosed |
| US-6833382-B2 | By muta-synthesis using a mutated micro-organism to influence the biosynthesis of at least one of the precursors of group B streptogramines; mutant strain employed is preferably derived from the strain S. pristinaespiralis SP92 | AVENTIS PHARMA S.A. (FR) | 2004-12-21 | — | — | US | disclosed |
| US-20020142947-A1 | STREPTOGRAMINS AND METHOD FOR PREPARING SAME BY MUTASYNTHESIS | AVENTIS PHARMA, S.A. | 2002-10-03 | — | — | US | disclosed |
| US-6384014-B1 | ANTIBIOTICS AS BACTERICIDES | AVENTIS PHARMA S.A. (FR) | 2002-05-07 | — | — | US | disclosed |
| US-6352839-B1 | PREPARING VIRGINIAMYCINS FROM AN ENGINEERED MICROORGANISMS, HAVING THE ABILITY TO PREVENT BIOSYNTHESIS OF THE PRECURSOR ANTIBIOTIC; THE MICROORGANISM IS CULTURED IN THE PRESENCE OF A SECOND PRECURSOR AND THE STREPTOGRAMIN ANALOG IS RECOVERED | AVENTIS PHARMA S.A. (FR) | 2002-03-05 | — | — | US | disclosed |
| EP-0773956-B1 | PURIFIED FORM OF STREPTOGRAMINES, PREPARATION OF SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | AVENTIS PHARMA SA (FR) | 2001-07-04 | — | — | EP | disclosed |
| EP-0773956-A1 | PURIFIED FORM OF STREPTOGRAMINES, PREPARATION OF SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | Aventis Pharma S.A. (FR) | 1997-05-21 | — | — | EP | disclosed |
| EP-0770132-A1 | STREPTOGRAMINES AND METHOD FOR PREPARING SAME BY MUTASYNTHESIS | Aventis Pharma S.A. (FR) | 1997-05-02 | — | — | EP | disclosed |
| WO-1996004298-A1 | PURIFIED FORM OF STREPTOGRAMINES, PREPARATION OF SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | RHONE-POULENC RORER S.A. (FR) | 1996-02-15 | — | — | WO | disclosed |
| WO-1996001901-A1 | STREPTOGRAMINES AND METHOD FOR PREPARING SAME BY MUTASYNTHESIS | RHONE-POULENC RORER S.A. (FR) | 1996-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020142947-A1 | STREPTOGRAMINS AND METHOD FOR PREPARING SAME BY MUTASYNTHESIS | EMG1, FBL, SMS | ALDH1A1 3856/4885ALOX5 3343/4885PKM 3557/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.